ORIGINAL RESEARCH

Ergothionine is associated with reduced mortality and decreased risk of cardiovascular disease

Einar Smith, Filip Ottosson, Sophie Hellstrand, Ulrika Ericson, Marji Orho-Melander, Céline Fernandez, Olle Melander

ABSTRACT

Objectives We recently identified a health conscious food pattern (HCFP) associated with reduced risk of cardiometabolic disease. However, the molecular events linking the healthy food pattern to reduced risk of cardiometabolic disease are unknown. Our aim was to identify plasma metabolites associated with the HCFP and test if such metabolites predict cardiometabolic disease and mortality.

Methods Using liquid-chromatography mass-spectrometry, 112 plasma metabolites were measured in 3236 participants without cardiovascular disease (CVD) and diabetes mellitus from the population-based Malmö Diet and Cancer study. Metabolites associated with the HCFP were identified using multivariable adjusted linear regressions followed by Bonferroni correction. The healthy dietary biomarkers were subsequently related to risk of cardiometabolic disease and mortality during long-term follow-up with multivariable adjusted Cox proportional hazards models.

Results During a median follow-up time of 21.4 years, 603 participants developed CVD, 362 developed diabetes mellitus and 843 participants died. Five healthy dietary biomarkers were associated with the HCFP at baseline (p<0.0004) and four predicted at least one of the studied end points (p<0.05). Ergothionine was the metabolite most strongly connected to the HCFP and was associated with a lower risk of coronary disease (HR per 1 SD increment of ergothionine, HR=0.85, p=0.01), cardiometabolic mortality (HR=0.79, p=0.002) and overall mortality (HR=0.86, p=4e-5).

Conclusions We identified that higher ergothionine was an independent marker of lower risk of cardiometabolic disease and mortality, which potentially can be induced by a specific healthy dietary intake.

INTRODUCTION

Dietary interventions have been suggested as a tool to improve cardiometabolic health to decrease the risk for type 2 diabetes, coronary artery disease (CAD), stroke and mortality. Randomised dietary intervention studies with hard outcomes are, however, challenging and there is controversy as to which dietary qualities would promote cardiometabolic health the most even though several ‘healthy/prudent’ data-driven dietary patterns have been found to associate with lower risk of cardiometabolic disease in observational prospective studies.

Understanding the molecular events resulting from dietary intakes, and their relationship to disease and health outcomes would facilitate future intervention studies through identification of diet-modifiable metabolic pathways and disease mechanisms.

Metabolomics can be used to measure how the levels of circulating metabolites are connected to dietary intakes. A large number of metabolites in the human circulation derive directly from the digestion and metabolism of food components and constitute the food metabolome. Both endogenous plasma metabolites and metabolites from the food metabolome have been shown to correlate with certain dietary patterns estimated using questionnaires on dietary intake in cohort studies, and with certain food items in randomised controlled feeding trials. The connection between diet and the metabolome is particularly interesting because circulating levels of specific metabolites have previously been shown to predict future risk of type 2 diabetes, CAD and premature mortality. By combining data from dietary intake, metabolomics and clinical outcomes, certain metabolites could be identified as associated with both a healthy diet and cardiometabolic health, thus pinpointing potential mechanisms of action of diet at the molecular level and candidate substances for future interventions by randomised controlled trials aiming to improve cardiometabolic health.

Here, we measured fasting plasma levels of 112 metabolites from the baseline examination of a Swedish population-based prospective cohort study, the Malmö Diet and Cancer study, comprising 3236 individuals without cardiovascular disease (CVD) and type 2 diabetes at study entry. We first assessed these metabolites’ association with a previously identified health conscious food pattern (HCFP) which was associated with protection from CVD and type 2 diabetes. Thereafter, HCFP-associated metabolites were related to incidence of type 2 diabetes, CVD, cardiovascular and overall mortality during a median follow-up time of 21 years. Our aim was to identify metabolites connected to both the HCFP and to protection from cardiometabolic disease in order to highlight metabolic pathways and mechanisms linking healthy dietary intake to cardiometabolic health.

METHODS

Study population

The Malmö Diet Cancer (MDC) study is a population-based prospective cohort study consisting of 28 098 individuals who attended a baseline examination between 1991 and 1996 in Malmö, Sweden. From this cohort, 6103 people were included in the current study population consisting of 3236 participants with no cardiovascular disease at baseline.

Additional material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/heartjnl-2019-315485).

Department of Clinical Sciences, Lund University, Malmö, Sweden

Correspondence to Mr Einar Smith, Department of Clinical Sciences, Lund University, Malmö 21428, Sweden; einar.smith@med.lu.se

CF and OM are joint senior authors.

Received 29 May 2019
Revised 19 September 2019
Accepted 1 October 2019
Cardiac risk factors and prevention

were randomly selected to participate in the cardiovascular cohort (MDC-CC), a cohort designed to study the epidemiology of carotid artery disease. All the participants in MDC-CC underwent a medical history and physical examination, laboratory assessment as well as a comprehensive dietary assessment and filled out a lifestyle questionnaire. All participants provided written informed consent. This research was done without patient involvement.

A random sample of 3833 MDC-CC participants was included for metabolite measurement as described below in the section “Metabolite measurements”. Participants with prevalent CAD (n=80), stroke (n=26) and/or type 2 diabetes (n=348) at baseline, as well as those with incomplete data on covariates (n=43) or dietary intake (n=120) were excluded from all analysis. The remaining 3236 participants constituted our study sample. Out of these participants, 2513 had information on adherence to the previously derived HCFP and constituted the study sample when circulating metabolites were related to the HCFP.

Dietary data
The MDC study used a diet history method that combined a 7-day-menu book, a 168-item food frequency questionnaire and a 45 min interview. The MDC method is described in detail elsewhere and in the (online supplementary file 1). In order to define a healthy dietary intake, we used the previously published HCFP derived from the MDC cohort by principal components analysis of participants’ food intakes. The HCFP was characterised by high intake of fibre-rich bread, breakfast cereals, fruits, vegetables, fish and low-fat yoghurt and by low intake of low-fibre bread.

Baseline data collection
Data on baseline smoking status and use of antihypertensive treatment were obtained from the baseline questionnaire. BMI was calculated as weight in kilograms divided by the square of the height in metres. Systolic and diastolic blood pressure were measured after 10 min of rest in the supine position. Leisure time physical activity was assessed by asking the participants to estimate the number of minutes per week they spent on 17 different activities. The duration was multiplied with an activity-specific intensity coefficient and an overall leisure time physical activity score was created.

Laboratory analyses were conducted on overnight fasted blood samples obtained at baseline examination. Analyses of plasma lipids and whole blood glucose were performed according to standard procedures at the Department of Clinical Chemistry, Skåne University Hospital in Malmö, which is linked to a national accreditation control system. The levels of low-density lipoprotein (LDL) cholesterol were calculated using the Friedewald formula.

End point definition
The end point definition is further explained in the supplementary material. Briefly, end points were retrieved by linking the 10-digit Swedish personal identification number with previously used and validated registers. CAD was defined as coronary artery revascularisation, fatal or non-fatal myocardial infarction or death due to ischaemic heart disease.

Metabolite measurements
Profiling of plasma metabolites was performed using LC-MS and has previously been described in details and is further explained in the supplementary material. Measured metabolites are listed in the in-house metabolite library (online supplementary table 1).

Statistical analyses
R (V.3.5.1) was used for all statistical analyses. Due to non-normality, metabolite data were log-transformed and scaled to multiples of 1 SD and centred on zero prior to statistical analysis.

The associations between baseline fasting levels of circulating metabolites and the HCFP previously described were analysed using linear regression models. The analyses were adjusted for age, sex, BMI, fasting glucose, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, systolic blood pressure, antihypertensive treatment, season for dietary data collection, alcohol intake and smoking status. In this initial analysis, associations were considered significant at a Bonferroni level p value limit of <0.00044. To test if the associations were independent of physical activity, sensitivity analysis was performed in the participants with complete data on physical activity (n=2323).

To assess associations between the metabolites that were associated with the HCFP and specific food groups, a correlation matrix with Pearson’s correlation coefficients was created. We compared the levels of metabolites with 10 selected food groups: fish and shellfish, fruits, vegetables, fermented milk, wholegrain portions, processed meat, non-processed red meat, root vegetables, leafy vegetables and sugar-sweetened beverages.

The five metabolites which associated significantly with the HCFP were in a first step related to the outcomes of incident CAD, type 2 diabetes, stroke, cardiovascular mortality and overall mortality using age-adjusted and sex-adjusted Cox proportional hazard models.

To visualise the relationships between the levels of healthy dietary biomarkers and morbidity and mortality, metabolite levels were divided into four quartiles and one Kaplan-Meier estimator per quartile was created.

Metabolites that were significant in the sex-adjusted and age-adjusted Cox regressions were further analysed in Cox regression models adjusted for age, sex, BMI, fasting glucose, LDL cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, antihypertensive treatment, alcohol intake and smoking status. Schoenfeld residuals test was used to check the proportional hazard assumptions. To test if the Cox regression models were independent of physical activity, sensitivity analysis was performed in the participants with complete data on physical activity (n=2993).

Lastly, association between ergothionene quartiles and risk factors for cardiometabolic disease were analysed.

RESULTS
General characteristics of the study population
The average baseline age of the participants was 57.4 years at baseline and 61% were female (table 1). Among the 3236 MDC-CC participants free from type 2 diabetes, CAD and stroke at the baseline, we identified 362 incident cases of type 2 diabetes, 316 of CAD and 271 of stroke during a median follow-up time of 21.4 years. During the same follow-up time, 843 participants died, of whom 229 died of cardiovascular causes.

Identification of healthy dietary biomarkers
Among the 112 measured metabolites, 5 showed significant positive associations with the HCFP and 1 had a significant negative association in the linear regression models adjusted for traditional cardiovascular risk factors (Bonferroni adjusted cut-off p<0.00044) (figure 1 and online supplementary table
Cardiac risk factors and prevention

Table 1  Study participants with complete data after exclusion of participants with prevalent diabetes mellitus, coronary artery disease and stroke

<table>
<thead>
<tr>
<th></th>
<th>Study participants n=3236 mean±SD or %</th>
<th>Study participants with complete dietary data n=2513 mean±SD or %</th>
<th>Study participants with complete data on physical activity n=2993 mean±SD or %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>57.4±6.0</td>
<td>57.4±6.0</td>
<td>57.4±6.0</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>61%</td>
<td>60%</td>
<td>61%</td>
</tr>
<tr>
<td>Smokers</td>
<td>27%</td>
<td>28%</td>
<td>27%</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.3±3.7</td>
<td>25.3±3.7</td>
<td>25.3±3.7</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>141±19</td>
<td>141±19</td>
<td>141±19</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>86.5±9.3</td>
<td>86.4±9.3</td>
<td>86.4±9.4</td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>4.90±0.43</td>
<td>4.90±0.43</td>
<td>4.90±0.44</td>
</tr>
<tr>
<td>Fasting triglycerides (mmol/L)</td>
<td>1.25±0.59</td>
<td>1.23±0.57</td>
<td>1.24±0.58</td>
</tr>
<tr>
<td>Fasting HDL cholesterol (mmol/L)</td>
<td>1.42±0.37</td>
<td>1.42±0.37</td>
<td>1.42±0.37</td>
</tr>
<tr>
<td>Fasting LDL cholesterol (mmol/L)</td>
<td>4.16±0.99</td>
<td>4.13±0.96</td>
<td>4.16±0.98</td>
</tr>
<tr>
<td>Antihypertensive treatment</td>
<td>13%</td>
<td>11%</td>
<td>13%</td>
</tr>
<tr>
<td>Alcohol intake (g/day)</td>
<td>10.1±11.7</td>
<td>10.4±11.8</td>
<td>10.2±11.7</td>
</tr>
</tbody>
</table>

Values are displayed as mean±SD or percentage.
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

2). Ergothioneine displayed the most significant association with the HCFP followed by proline betaine, acetylornithine and pantothenate. The metabolite that associated negatively with the HCFP was urobilin. In sensitivity analyses, adjusting the linear regression models for physical activity did not change the associations (online supplementary table 3).

Figure 1  Identifying healthy dietary biomarkers using linear regression models. Five metabolites are found to be positively associated with the health conscious food pattern (HCFP) independent of traditional cardiovascular risk factors and one metabolite to be negatively associated. The linear regression models between the HCFP and fasting metabolite levels were adjusted for age, sex, body mass index, fasting glucose, fasting low-density lipoprotein cholesterol, fasting high-density lipoprotein cholesterol, fasting triglycerides, systolic blood pressure, antihypertensive treatment, season for dietary sampling, alcohol intake and smoking status. Beta represents a quintile increase or decrease in the five quintile scaled HCFP per SD increment of a metabolite. The cut-off for significance (p=0.00044) was calculated using Bonferroni correction, n=2513.
Healthy dietary biomarkers and food groups
All of the identified healthy dietary biomarkers as well as urobilin were significantly correlated with several food groups (online supplementary figure 1). The strongest correlation was observed between ergothioneine and vegetable intake, with a Pearson’s correlation coefficient of 0.2 (p=2e-29).

Dietary biomarkers and cardiovascular end points
Next, we investigated association between plasma levels of the five healthy dietary biomarkers and of urobilin, and incidence of cardiometabolic disease as well as overall and cardiovascular mortality. Four healthy dietary biomarkers as well as urobilin were associated with at least one cardiometabolic disease end point in the Cox proportional hazards models adjusted for sex and age (figure 2). Ergothioneine was the metabolite most significantly associated with a lower risk of CAD, cardiovascular mortality and overall mortality. Acetylornithine remained significantly associated with a lower risk for cardiovascular mortality, overall mortality and stroke. Proline betaine was associated with a lower risk for CAD and overall mortality. Methylproline was significantly associated with a lower risk for overall mortality. Urobilin remained significantly associated with an increased risk of overall mortality and type 2 diabetes. The proportional hazard assumptions were met for all models except the model with urobilin and overall mortality (online supplementary table 4).

In sensitivity analyses, adjusting the Cox regression models for physical activity did not affect the HRs (online supplementary table 5).

Metabolite levels and cardiovascular risk factors
The associations between traditional cardiovascular risk factors and ergothioneine were overall weak, except for alcohol intake, which was strongly associated with ergothioneine levels, and for HDL cholesterol, which was negatively associated (online supplementary table 6).

DISCUSSION
Main findings
In this population-based prospective study we identify plasma metabolites that, for the first time, tie together an HCFP and a lower risk of cardiometabolic morbidity and mortality during a long-term follow-up. In particular, increased level of the amino acid ergothioneine was strongly and independently associated with both HCFP and a lower risk of future CAD and cardiovascular and all-cause mortality. Overall, our findings suggest novel pathways linking diet to cardiometabolic health.

Healthy dietary biomarkers
Several of the metabolites we found to be associated with the HCFP have previously been correlated with self-reported intake of specific food groups or items. Ergothioneine exists in many
Ergothioneine: a biomarker of both healthy diet and low cardiometabolic risk

Ergothioneine had the strongest association with the HCPF and also the most evident protective associations with cardiometabolic morbidity and mortality independent of traditional risk factors. Our results thus suggest ergothioneine as a biomarker of both healthy dietary intake and of low risk of future cardiometabolic disease. Ergothioneine has earlier been shown to protect rodents from ischaemic reperfusion injury and has also previously suggested to be an anti-oxidant with potential beneficial effects on the human body. Ergothioneine differs from other suggested anti-oxidants by having a specific transporter that has been suggested to be upregulated in areas of inflammation, providing ergothioneine a potential for a more controlled anti-oxidant function. Having higher levels of ergothioneine could in a reactionary manner protect from oxidative stress, which is thought to be an important factor in the pathogenesis of CVD and could explain our findings.

A recent study conducted in healthy humans showed that oral administration of ergothioneine increased the levels of circulating ergothioneine as well as decreased levels of some biomarkers of oxidative damage. Intervention trials with randomised treatment regimen design, are required to investigate if this potential anti-oxidant effect can decrease the risk of cardiometabolic disease.

The positive correlation between ergothioneine and alcohol intake has previously been demonstrated, an association that can either be explained by ergothioneine being present in alcoholic beverages, or by alcohol changing the absorption efficiency of ergothioneine present in other dietary sources.

Other dietary biomarkers and cardiometabolic disease

In our study, proline betaine showed an association with a decreased risk for CAD and overall mortality but the latter association vanished after adjustment for traditional risk factors. In support for a role of proline betaine in CAD protection, a previous study showed that addition of proline betaine to endothelial cells cultured in glucotoxic conditions ameliorated the detrimental effect of high glucose on the endothelial cells. The association could also be explained by proline betaine being a confounding variable for another compound; proline betaine is a known biomarker for citrus fruit, which contains many other metabolites not measured using our method.

To our knowledge, the observed associations between decreased risk of cardiometabolic end points and the healthy dietary biomarkers acetylornithine and methylproline represent novel findings. Acetylornithine was the only metabolite associated with a lower risk for stroke in the fully adjusted models, further studies are needed to investigate the potential mechanism linking high acetylornithine levels to better cardiometabolic health. Urobilin has to our knowledge not previously been associated with an increased risk of type 2 diabetes or mortality, but recently associated with an increased risk of heart failure. More research is needed to explain the association between haemoglobin breakdown components and CVD.

---

Figure 3 Fully adjusted Cox regressions. Cox proportional hazard models comparing the health conscious dietary biomarker levels with risk for overall and cardiovascular mortality as well as for incident stroke, diabetes mellitus and coronary artery disease during the median follow-up time of 21.4 years. The models were adjusted for age, sex, body mass index, fasting glucose, fasting low-density lipoprotein cholesterol, fasting high-density lipoprotein cholesterol, fasting triglycerides, systolic blood pressure, antihypertensive treatment, alcohol intake and smoking status. The HR is calculated as the increase or decrease in risk per 1 SD increment of metabolite levels with 95% CI, n=3236. CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.
Strengths and limitations
The large and prospective population-based cohort design, with >20 years of follow-up and validated end points, comprise major strengths of our study. Moreover, we benefit from high-quality dietary data from the thorough MDC diet assessment method. As the dietary intakes, cardiometabolic risk factors and the metabolomics data were only collected at baseline of the study, changes in these factors cannot be studied or adjusted for. However, the study participants in MDC were middle-aged or older at baseline and have most likely in general rather established dietary habits less prone to radical changes.

As in all observational studies, it is not possible to prove that the observed associations between the healthy dietary biomarkers and end points are causal. However, by using a prospective study design and models fully adjusted for traditional risk factors, we think that our results provide strong base for future intervention studies examining the observed diet-metabolite-disease associations. Moreover, the healthy diet-associated metabolites could be useful biomarkers of diet adherence.

CONCLUSION
We identify biomarkers associated independently from traditional risk factors with a healthy food pattern and incidence of cardiometabolic morbidity and mortality. The metabolite ergothioneine had the most significant correlation to the healthy food pattern and was the most predictive for low risk of CVD. Our results encourage controlled specific dietary intervention studies, and ergothioneine supplementation, aimed at testing if raising ergothioneine plasma concentration may reduce risk of cardiometabolic disease.

Acknowledgements
The authors would like to thank the staff and participants of the Malmö Diet and Cancer Study.

Contributors
ES contributed to study design, acquisition and interpretation of data, statistical analyses and drafted the manuscript. UE, SH and FO contributed to collection and interpretation of data and statistical analysis. MO-M assisted in data interpretation. CF and OM contributed to study concept and design, interpretation of data and statistical analyses. All authors made intellectual contributions to drafting and/or revising the manuscript and approved the final version. ES, CF, FO and OM had full access to the data. The manuscript is original research, has not been published and is not submitted to be considered for publication elsewhere, in whole or in part, in any language. There are no potentially overlapping papers in preparation, submission or published. The authors declare that there is no duality of interest associated with this manuscript.

Funding
This study was funded by Crafoordska Stiftelsen, Vetenskapsradet, Novo Nordisk, Åke Wiberg Stiftelse, Göran Gustafsson Stiftelse för Naturvetenskaplig och Medicinsk forskning, Knut och Alice Wallenbergs Stiftelse, Kungliga Fysiografiska Sällskapet i Lund, the Ernlund Lundström Research Foundation, Region Skåne, Skåne University Hospital, European Foundation for the Study of Diabetes (grant no: EFSD 2015/338), Härt-Lungfonden. H2020 European Research Council, Diabetesfonden, Director Albert Pålshons Stiftelse. OM was supported by Knut and Alice Wallenberg Foundation, Göran Gustafsson Foundation, the Swedish Heart and Lung Foundation, the Swedish Research Council, the Novo Nordisk Foundation, Region Skåne, Skåne University Hospital. CF was supported by the Albert Pålshon Research Foundation, the Crafoord Research Foundation, the Ernlund Lundström Research Foundation, the Royal Physiographic Society of Lund and the Åke Wiberg Foundation. MO-M was supported by the European Research Council (Consolidator grant nr 649021, Orho-Melander), the Swedish Research Council, the Swedish Heart and Lung Foundation, the Novo Nordic Foundation, the Swedish Diabetes Foundation, the European Foundation for Study of Diabetes (EFSD 2015/338) and the Region Skåne, Skåne University Hospital. FO was supported by the Ernlund Lundström Research Foundation.

Competing interests
None declared.

Patient consent for publication
Not required.

Ethics approval
The study was approved by the Ethics Committee of Lund University, Lund, Sweden (LU 51–90).

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Elina Smith http://orcid.org/0000-0002-4150-2459

REFERENCES
Cardiac risk factors and prevention


